{"id":56962,"date":"2026-02-12T21:14:49","date_gmt":"2026-02-12T13:14:49","guid":{"rendered":"https:\/\/flcube.com\/?p=56962"},"modified":"2026-02-12T21:14:51","modified_gmt":"2026-02-12T13:14:51","slug":"ubrigene-biosciences-partners-with-bristar-immunotech-on-universal-star-t-cell-therapy-cdmo","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56962","title":{"rendered":"uBriGene Biosciences Partners with BriSTAR Immunotech on Universal STAR-T Cell Therapy CDMO"},"content":{"rendered":"\n

uBriGene Biosciences<\/strong>, a China-based advanced therapy medicinal product (ATMP) CDMO<\/strong>, has entered a strategic partnership<\/strong> with BriSTAR Immunotech<\/strong>, a clinical-stage cell therapy company<\/strong>, to provide full-process CDMO services<\/strong> for universal STAR-T therapy<\/strong> targeting severe autoimmune diseases<\/strong>. The collaboration integrates uBriGene’s AAV vector manufacturing expertise<\/strong> with BriSTAR’s STAR-T cell technology<\/strong> to overcome autologous therapy bottlenecks<\/strong> and accelerate clinical translation<\/strong> of this next-generation cell therapy platform<\/strong>.<\/p>\n\n\n\n

Partnership Structure<\/h2>\n\n\n\n
Element<\/th>Detail<\/th><\/tr><\/thead>
CDMO Partner<\/strong><\/td>uBriGene Biosciences (ATMP-focused CDMO)<\/td><\/tr>
Cell Therapy Partner<\/strong><\/td>BriSTAR Immunotech (clinical-stage, China)<\/td><\/tr>
Modality<\/strong><\/td>Universal STAR-T therapy (allogeneic cell therapy)<\/td><\/tr>
Target Indications<\/strong><\/td>Severe autoimmune diseases; oncology (future expansion)<\/td><\/tr>
uBriGene Services<\/strong><\/td>AAV vector process development, GMP manufacturing, Sino-US IND filing support<\/td><\/tr>
Strategic Goal<\/strong><\/td>Clinical translation and industrialization of STAR-T platform<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Technology Integration & Innovation<\/h2>\n\n\n\n
Component<\/th>Technology<\/th>Strategic Value<\/th><\/tr><\/thead>
STAR-T Cells<\/strong><\/td>Synthetic T-cell receptor and antigen receptor<\/strong> platform<\/td>Enhanced specificity and potency vs. conventional CAR-T; universal\/off-the-shelf capability<\/td><\/tr>
AAV Vectors<\/strong><\/td>Adeno-associated viral delivery<\/strong> for genetic modification<\/td>Efficient, stable gene transfer; established safety profile<\/td><\/tr>
Universal (Allogeneic) Format<\/strong><\/td>Off-the-shelf<\/strong> vs. patient-specific autologous<\/td>Manufacturing scalability<\/strong>, reduced cost<\/strong>, immediate availability<\/strong> for acute autoimmune flares<\/td><\/tr>
Combination Rationale<\/strong><\/td>AAV-mediated genetic engineering of STAR-T cells<\/td>Streamlined manufacturing<\/strong>; consistent product quality; regulatory pathway clarity<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Target Indications & Market Context<\/h2>\n\n\n\n
Therapeutic Area<\/th>Application<\/th>Unmet Need<\/th><\/tr><\/thead>
Severe Autoimmune Diseases<\/strong><\/td>Systemic lupus erythematosus, multiple sclerosis, rheumatoid arthritis<\/td>Refractory patients<\/strong> failing biologics; autologous CAR-T too slow\/costly<\/strong> for acute management<\/td><\/tr>
Oncology (Future)<\/strong><\/td>Solid tumors, hematologic malignancies<\/td>Allogeneic CAR-T limitations<\/strong> (GvHD, persistence); STAR-T safety and efficacy potential<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n